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Background: Bacterial DNA gyrase is a validated target for antibacterial chemotherapy. It consists of two subunits,
GyrA and GyrB, which form an A2B2 complex in the active enzyme. Sequence alignment of Mycobacterium
tuberculosis GyrB with other bacterial GyrBs predicts the presence of 40 potential additional amino acids at the GyrB
N-terminus. There are discrepancies between the M. tuberculosis GyrB sequences retrieved from different databases,
including sequences annotated with or without the additional 40 amino acids. This has resulted in differences in
the GyrB sequence numbering that has led to the reporting of previously known fluoroquinolone-resistance
mutations as novel mutations.
Findings: We have expressed M. tuberculosis GyrB with and without the extra 40 amino acids in Escherichia coli and
shown that both can be produced as soluble, active proteins. Supercoiling and other assays of the two proteins
show no differences, suggesting that the additional 40 amino acids have no effect on the enzyme in vitro. RT-PCR
analysis of M. tuberculosis mRNA shows that transcripts that could yield both the longer and shorter protein are
present. However, promoter analysis showed that only the promoter elements leading to the shorter GyrB (lacking
the additional 40 amino acids) had significant activity.
Conclusion: We conclude that the most probable translational start codon for M. tuberculosis GyrB is GTG (Val)
which results in translation of a protein of 674 amino acids (74 kDa).
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Introduction
Bacterial DNA gyrase is a validated target for antibacter-
ial chemotherapy [1]. It is a member of the DNA topo-
isomerase family of enzymes, which are responsible for
maintaining and manipulating the topological state of
DNA [2,3]. These enzymes are required for vital pro-
cesses such as DNA replication, transcription, recombin-
ation and chromatin remodelling. Topoisomerases can
be classified into two types, I and II, dependent on
whether their reactions involve transient cleavage of one
(I) or both (II) strands of DNA. Due to the important
role played by topoisomerases in maintaining cell viabil-
ity, they are attractive clinical targets for chemothera-
peutics [1,4,5].* Correspondence: tony.maxwell@jic.ac.uk
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reproduction in any medium, provided the orDNA gyrase is a type II topoisomerase that consists of
two subunits, GyrA and GyrB, which form an A2B2 com-
plex in the active enzyme [1,6]. Gyrase introduces negative
supercoils into DNA, in addition to catalysing relaxation
and decatenation. The supercoiling and decatenation reac-
tions require ATP hydrolysis, which occurs in the GyrB
subunits. The absence of gyrase in most eukaryotes and
its essentiality in bacteria have made it an ideal target for
antimicrobial agents [1].
Tuberculosis (TB) is the world’s most deadly bacterial
disease with around a third of the world’s population
infected and over 1 million deaths every year [7]. Al-
though treatments are available, drug-resistant strains,
MDR (multi-drug resistant) and XDR (extensively drug re-
sistant) TB, pose serious problems. Moxifloxacin, a fluoro-
quinolone that targets DNA gyrase, has been successfully
used against Mycobacterium tuberculosis, particularly
MDR strains [8]. The search for new anti-TB agents in-
volves the further exploitation of M. tuberculosis gyrase asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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derstanding of this enzyme.
Most of our current information about gyrase concerns
the enzyme from Escherichia coli, a Gram-negative bacter-
ium, with limited information about gyrase from M. tuber-
culosis [9], which is generally described as a Gram-positive
bacterium. In M. tuberculosis the two genes encoding
DNA gyrase, gyrB and gyrA, are located adjacent to each
other, and although there is a separate promoter for gyrA
(PA), the primary transcript appears to be dicistronic [10].
Analysis of the region upstream of gyrB suggests there are
multiple promoters, but it appears that most of the tran-
scripts originate from PB1 with the others potentially in-
volved in the fine-tuning of transcription [10].
There are significant discrepancies in the M. tuberculosis
GyrB sequences retrieved from different databases. For ex-
ample, in the case of NCBI code CAB02426 for M. tuber-
culosis H37Rv GyrB, 40 additional amino acids are present
in the sequence starting with amino acids MGKNEARRSA.
While the same protein cross-referenced in UniProtKB/
Swiss-Prot as P0C5C5 lacks these additional amino acids; it
is 674 amino acids and starts with the amino acid sequence:
MAAQKKKAQD. This is not uniform across UniProtKB/
Swiss-Prot as in other M. tuberculosis strains, such as M.
tuberculosis T92, the GyrB sequence (UniProtKB/Swiss-
Prot: D5XPA3) also has the 40 additional amino acids and
starts with MGKNEARRSA. Similarly, in the case of
M. bovis AF2122/97 both the NCBI (CAD92867) and
UniProtKB/Swiss-Prot (Q7U312) databases indicate the
presence of an additional 40 amino acids at the GyrB N-
terminus. Re-annotation of the M. tuberculosis H37Rv gene
sequence [11] suggested that GyrB is a protein of 714
amino acids and MW 78.4 kDa, These various discrepan-
cies in GyrB sequence annotation have led to differences in
sequence numbering, which in turn has resulted in the
reporting of previously known fluoroquinolone resistance
mutations as novel mutations [12].
In this paper we investigate the start codon for M.
tuberculosis GyrB sequence by promoter and transcript
analysis, and studies on the expressed protein.
Materials and methods
Preparation and purification of proteins
M. tuberculosis gyrB sequences were amplified from M.
tuberculosis genomic DNA and cloned into TOPO® clon-
ing vectors followed by sub-cloning into pET20 using
the ClonableTM Ligation kit (Novagen). Expression and
purification of the GyrB and GyrA proteins were as pre-
viously described [13].
Enzyme assays
M. tuberculosis DNA gyrase assays (supercoiling, relaxation
and decatenation) were performed as described previously
[13]. Peptide mass fingerprinting and mass spectrometryanalyses were carried out by Gerhard Saalbach (John Innes
Centre Proteomics Shared Facility).
RT-PCR
Total RNA was extracted from standing cultures of M. tu-
berculosis H37Rv, as previously described [14], and DNase
treated prior to cDNA synthesis [15]. cDNA was synthe-
sized from 1 μg of total RNA using SuperScript II RT
(Invitrogen) and random primers (Invitrogen) according
to the manufacturer’s instructions; an RT-minus control
for each sample was also included and processed in tan-
dem. To identify which transcripts were present, four for-
ward primers were designed: F1 (5′-CAC GGC GCG
GTT AGA TGG GTA A-3’), which binds near the start of
the region corresponding to the additional 40 amino acids
at nucleotide positions 5109–5130 [16]; F2 (5′-TGG GTA
AAA ACG AGG CCA GAA GAT C-3′) corresponds to
the start of the region encoding the additional 40 amino
acids at positions 5124–5148; F3 (5′-CGA CTC AAC
CGC ATG CAC GCA-3′), which corresponds to the mid-
dle of the region comprising the 40 amino acids at pos-
ition 5195–5215; F4 (5′-CCA GAA AAA GAA GGC
CCA AG-3′), which corresponds to 5 nucleotides after
the end of the 40 amino acids at positions 5248–5267;
these were used in combination with a single reverse pri-
mer R (5′-ATA ACC GGC CAT CGC CTC GT-3′), as
shown in Figure 1A. RT-PCR reaction mixes contained
GoTaq PCR Mastermix (Promega), 10 pmol forward pri-
mer, 10 pmol reverse primer R, and 100 ng cDNA. Cycling
conditions were: 25 cycles of 94°C for 30“, 56°C for 30”,
and 72°C for 1’, followed by 72°C for 5’ final extension.
The amplified products were run on a 1% agarose gel and
visualized with ethidium bromide staining.
Promoter analysis
Primer pairs Met-F: 5′-AGT ACT CAC GTC GAT CGG
CCC AGA ACA AGG CGC- 3′ and Met-R: 5′-CCC
GGG CAT CTA ACC GCG CCG TGC-3′ or Val-F: 5′-
AGT ACT CAC GTC GAT CGG CCC AGA ACA AGG
CGC-3′ and Val-R: 5′-CCC GGG CAC GAT CCG AAT
ACT CTC CTC AGG G-3′ were used to amplify the up-
stream regions. The thermocycler program used was:
2 min denaturation at 94°C, 25 cycles of 94°C for 15’, 55°C
for 1’, and 72°C for 2’, with a final extension at 72°C for 10’.
PCR products were cloned into the pGEM-T easy vector
(Promega), sequence verified, and sub-cloned as ScaI frag-
ments into pSM128 [17] to construct the plasmids, which
were called: pSM128-Met, carrying 128 bp upstream of
the predicted transcriptional start site (nucleotides 4998–
5125, ending with Met); and pSM128-Val (4998–5242)
carrying a larger 245 bp upstream region ending with Val
(GTG). Plasmids were introduced into M. tuberculosis
H37Rv by electroporation and selected on streptomycin.
Three individual transformants were inoculated into 10 ml
MGKNEARRSALAPDHGTVVCDPLRRLNRMHATPEESIRI   VAAQKKKAQDE………… M. tuberculosis GyrB
F1 F2 F3 F4 R
Upstream sequence 40 additional amino acids
gDNA Blank ( no template)cDNA-RTcDNA+ RT
M    F1 F2   F3      F4 F1    F2  F3 F4 F1    F2  F3     F4 F1    F2   F3  F4
A
B
Figure 1 Identification of mRNA transcripts for M. tuberculosis gyrB. (A) Schematic showing the position of primers (F1, F2, F3, F4, and R)
used for RT-PCR. (B) Products from RT-PCR reactions were analysed by agarose gel electrophoresis. Left primers used are indicated above the
lanes and correspond to Figure 1A; M – markers (1 kb ladder); cDNA+RT: plus reverse transcriptase; cDNA-RT: no reverse transcriptase; gDNA:
genomic DNA; blank: no template control.
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liquid medium supplemented with 10% (vol/vol) OADC
(oleic acid, bovine serum albumin, d-glucose, catalase;
Becton Dickinson) and 0.05% (wt/vol) Tween 80). Cell-
free extracts were prepared and β-galactosidase assays
were performed, as previously described [18].
Results
Sequence alignment of M. tuberculosis GyrB
As established previously [12] there have been several
numbering systems reported for M. tuberculosis GyrB,
which has led to considerable confusion in relation to
the location of quinolone-resistance mutations. Figure 2
shows a sequence alignment of M. tuberculosis GyrBFigure 2 Multiple sequence alignment of bacterial GyrBs. Amino acid s
with other bacterial GyrBs using ClustalW 1.83 [19]. S. coelicolor = Streptomyce
Bo. burgdorferi = Borrelia burgdorferi; C. jejuni = Campylobacter jejuni; N. gonorrwith other bacterial GyrBs, highlighting a stretch of 40
amino acids at the N-terminus, the presence of which
has contributed to the confusion in amino acid numbering.
We set out to establish the significance of these additional
amino acids and whether the protein produced in M.
tuberculosis includes this sequence.
Enzyme activity of GyrBs with and without the additional
40 amino acids
Expression plasmids (based on pET20) were constructed
for production of GyrBs with and without the additional
40 amino acids, and the resulting proteins were purified
by affinity chromatography and by gel filtration. The
presence of the additional 40 amino acids in the longerequence alignment of Mycobacterium tuberculosis GyrB (NCBI sequence)
s coelicolor; St. aureus = Staphylococcus aureus; B. subtilis = Bacillus subtilis;
hoeae = Neisseria gonorrhoeae; E. coli = Escherichia coli.
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mass spectrometry analysis (data not shown).
The two GyrB proteins were complexed with M. tu-
berculosis GyrA and the supercoiling, relaxation and
decatenation activities were measured as previously de-
scribed [13]. We found that there was no significant ef-
fect of the additional amino acids on these activities, forA
B
C
GCGACACCTA CGGATAACAC GTCGATCGGC CCAGAA
GAGCCTCGAG GACGAAGCGG ATCCGTATGC CGGACG
GTCCGACGCA CGGCGCGGTT AGATGGGTAA AAACGA
CGATCACGGT ACAGTGGTGT GCGACCCCCT GCGGCG
TGAGGAGAGT ATTCGGATCG TGGCTGCCCA GAAAAA
Figure 3 Promoter activity determined in M. tuberculosis. (A) Upstream
to give pSM128-Met and pSM128-Val respectively. (B) M. tuberculosis recom
β-galactosidase activity measured. Transformants were obtained for pSM12
nucleotides 4998–5125, upstream of the ORF for GyrB) and pSM128-Met (c
deviation from three independent transformants tested in duplicate. (C) M
gyrB and its upstream sequence. The predicted ribosome binding site is in
the gyrB coding sequence is in italics with the Val start codon underlined.example the supercoiling activities of the two enzymes
are nearly identical (Additional file 1: Figure S1), and no
effect on the sensitivity of the enzyme to novobiocin
(data not shown); the binding site for novobiocin lies in
the N-terminal domain of GyrB [1]. This strongly sug-
gests, in vitro at least, that the additional 40 amino acids
are of no functional significance.CAAG GCGCTCCGGT CCCGGCCTGA 5040
TCGG GACGCACCAG GAAGAAAGAT 5100
GGCC AGAAGATCGG CCCTGGCGCC 5160
ACTC AACCGCATGC ACGCAACCCC 5220
GAAG GCCCAAGACG AATACGGCGC 5280
regions of GyrB ending in Met and Val were cloned into pSM128
binants were grown as described in Materials and Methods, and
8 (empty vector control); pSM128-Val (containing M. tuberculosis
ontaining nucleotides 4998–5242). Data are mean +/− standard
. tuberculosis genome sequence 4981–5280 that includes the start of
bold and underlined; the predicted promoter elements are in bold;
The annotations are consistent with earlier work [10].
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We wanted to determine whether GyrB was produced as
the longer or shorter protein; as a first step we analysed
the transcripts. RT-PCR was performed to determine
which GyrB mRNA transcripts are produced in M. tu-
berculosis under normal aerobic growth. Primers were
designed to distinguish between longer and shorter tran-
scripts which could encode for longer or shorter pro-
teins respectively (Figure 1A). As shown in Figure 1B,
PCR products were obtained with all primer sets (F1, F2,
F3, F4) indicating that mRNA was being produced that
could potentially encode the longer protein. The identity
of the products obtained was confirmed by sequencing.
This RT-PCR experiment indicates that the nucleotide
sequence that could encode the 40 amino acids is
transcribed.Promoter analysis
From the enzyme activity assays above it appears that
the additional 40 amino acids at the N-terminus of GyrB
have no functional significance, but the mRNA analysis
suggests the possibility that there are RNA species that
can encode these 40 amino acids. In order to identify
the translational start site, we analysed expression of the
LacZ reporter gene in M. tuberculosis. Two plasmids
were tested for activity: pSM128-Met contained the re-
gion upstream of the additional 40 amino acids termin-
ating at ATG (5125), and pSM128-Val carrying the
region upstream of the shorter GyrB terminating at
GTG (5242) (Figure 3). Plasmid pSM128-Met showed
no significant promoter activity (Figure 3B), while
pSM128-Val demonstrated high level promoter activity
(740 MU ± 63). (A comparable series of experiments in-
volving the introduction of these plasmids into M.
smegmatis gave very similar results; data not shown).
These data suggest that, under these growth conditions,
the expression of GyrB is from a promoter located up-
stream of the valine start codon and that the shorter
protein is produced, i.e. without the additional 40 amino
acids.Discussion
Sequence alignments of GyrBs from different bacterial
species suggest that 40 additional amino acids could
potentially be present at the M. tuberculosis GyrB N-
terminus (Figure 2). In order to study the effect of these 40
amino acids on enzyme activity, we expressed and purified
GyrB proteins in which the 40 amino acids were present
or absent and found that there is no apparent effect of the
additional amino acids on gyrase activity, as judged by
supercoiling, relaxation and decatenation assays in vitro.
RT-PCR experiments were performed, which showed
that the RNA sequence corresponding to the additional40 amino acids at the GyrB N-terminus is present at the
transcript level (Figure 1). However, promoter assays
(Figure 3B) showed that only the shorter GyrB would be
expressed at a significant level in vivo. These experi-
ments suggest that the promoter elements are present in
the region corresponding to the predicted 40 amino
acids at the GyrB N-terminus (Figure 3C). The presence
of transcripts containing the 40 amino acid region indi-
cates possible post-transcriptional events occurring be-
fore the mature GyrB is formed.
Conclusion
Taken together our results support M. tuberculosis GyrB
being a protein of 74,058.7 Da (674 amino acids) that
begins with the codon GTG (Val) at position 5240–5242
in the M. tuberculosis genome sequence [16]. A recent
paper also supports this conclusion [12].
Additional file
Additional file 1: Figure S1. Supercoiling assays of short and long GyrBs.
DNA supercoiling assays were carried out as described previously [13] with M.
tuberculosis GyrB proteins, with (+40) and without (−40) the additional 40
amino acids, complexed with GyrA. Enzyme concentrations are indicated
above the gel tracks and the topological forms of plasmid pBR322 are
indicated at the side: OC = nicked circular; Rel = relaxed; SC = supercoiled.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SK, ACB, TP and AM conceived the research ideas for the work. SK and ACB
carried out the experiments. TP and AM supervised the work. SK, ACB, TP and
AM wrote the manuscript. All authors read and approved the manuscript.
Acknowledgements
This work was supported by an EST early stage research scholarship, EU FP7
(to SK) and by grant BB/J004561/1 from BBSRC and the John Innes
Foundation to AM, and by European Union Project LSHP-CT-2005-018923.
We thank Fred Collin for comments on the manuscript.
Author details
1Department of Biological Chemistry, John Innes Centre Norwich Research
Park, Norwich NR4 7UH, UK. 2Barts and The London School of Medicine and
Dentistry, Queen Mary University of London, 4 Newark Street, London E1
2AT, UK. 3Present address: Novartis Institute of Biomedical Research, Basel
4056, Switzerland. 4Present address: Oxford Gene Technology, Begbroke
Science Park, Begbroke Hill, Woodstock Road, Begbroke OX5 1PF, UK.
Received: 14 February 2013 Accepted: 8 July 2013
Published: 15 July 2013
References
1. Collin F, Karkare S, Maxwell A: Exploiting bacterial DNA gyrase as a drug
target: current state and perspectives. Appl Microbiol Biotechnol 2011,
92(3):479–497.
2. Bates AD, Maxwell A: DNA Topology. Oxford: Oxford University Press; 2005.
3. Schoeffler AJ, Berger JM: DNA topoisomerases: harnessing and
constraining energy to govern chromosome topology. Q Rev Biophys
2008, 41(1):41–101.
4. Pommier Y, Leo E, Zhang H, Marchand C: DNA topoisomerases and their
poisoning by anticancer and antibacterial drugs. Chem Biol 2010,
17(5):421–433.
Karkare et al. BMC Research Notes 2013, 6:274 Page 6 of 6
http://www.biomedcentral.com/1756-0500/6/2745. Tse-Dinh YC: Exploring DNA topoisomerases as targets of novel
therapeutic agents in the treatment of infectious diseases. Infect Disord
Drug Targets 2007, 7(1):3–9.
6. Nollmann M, Crisona NJ, Arimondo PB: Thirty years of Escherichia coli
DNA gyrase: from in vivo function to single-molecule mechanism.
Biochimie 2007, 89(4):490–499.
7. Young D, Stark J, Kirschner D: Systems biology of persistent infection:
tuberculosis as a case study. Nat Rev Microbiol 2008, 6(7):520–528.
8. Takiff H, Guerrero E: Current prospects for the fluoroquinolones as
first-line tuberculosis therapy. Antimicrob Agents Chemother 2011,
55(12):5421–5429.
9. Aubry A, Fisher LM, Jarlier V, Cambau E: First functional characterization of
a singly expressed bacterial type II topoisomerase: the enzyme from
Mycobacterium tuberculosis. Biochem Biophys Res Commun 2006,
348(1):158–165.
10. Unniraman S, Chatterji M, Nagaraja V: DNA gyrase genes in
Mycobacterium tuberculosis: a single operon driven by multiple
promoters. J Bacteriol 2002, 184(19):5449–5456.
11. Camus JC, Pryor MJ, Medigue C, Cole ST: Re-annotation of the genome
sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002,
148(Pt 10):2967–2973.
12. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C,
Cambau E, Aubry A: A systematic review of gyrase mutations associated
with fluoroquinolone-resistant Mycobacterium tuberculosis and a
proposed gyrase numbering system. J Antimicrob Chemother 2012,
67(4):819–831.
13. Karkare S, Yousafzai F, Mitchenall LA, Maxwell A: The role of Ca2+ in the
activity of Mycobacterium tuberculosis DNA gyrase. Nucleic Acids Res
2012, 40(19):9774–9787.
14. Rustad TR, Harrell MI, Liao R, Sherman DR: The enduring hypoxic response
of Mycobacterium tuberculosis. PLoS One 2008, 3(1):e1502.
15. Brown AC, Eberl M, Crick DC, Jomaa H, Parish T: The nonmevalonate
pathway of isoprenoid biosynthesis in Mycobacterium tuberculosis is
essential and transcriptionally regulated by Dxs. J Bacteriol 2010,
192(9):2424–2433.
16. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV,
Eiglmeier K, Gas S, Barry CE 3rd, et al: Deciphering the biology of
Mycobacterium tuberculosis from the complete genome sequence.
Nature 1998, 393(6685):537–544.
17. Dussurget O, Timm J, Gomez M, Gold B, Yu S, Sabol SZ, Holmes RK, Jacobs
WR, Smith I: Transcriptional control of the iron-responsivefxbA gene by
the mycobacterial regulator IdeR. J Bacteriol 1999, 181(11):3402–3408.
18. Carroll P, James J: Assaying promoter activity using LacZ and GFP as
reporters. Methods Mol Biol 2009, 465:265–277.
19. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam
H, Valentin F, Wallace IM, Wilm A, Lopez R, et al: Clustal W and Clustal X
version 2.0. Bioinformatics 2007, 23(21):2947–2948.
doi:10.1186/1756-0500-6-274
Cite this article as: Karkare et al.: Identification of the likely translational
start of Mycobacterium tuberculosis GyrB. BMC Research Notes 2013 6:274.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
